Off-Label Use of Atypical Antipsychotics

McKean, Andreiv; Monasterio, Erik
May 2012
CNS Drugs;2012, Vol. 26 Issue 5, p383
Academic Journal
Licensed indications for medicines were designed to regulate the claims that can be made about a medicine by a pharmaceutical company. Off-label prescribing (i.e. prescribing a drug for an indication outside of that for which it is licensed) is legal and an integral part of medical practice. In psychiatry, off-label prescribing is common and gives clinicians scope to treat patients who are refractory to standard therapy or where there is no licensed medica-tion for an indication. However, efficacy or safety of such off-label use may not be established. There is a growing list of licensed indications for atypical antipsychotics (AAP) beyond schizophrenia and bipolar affective disorder, and also more evidence for other indications where pharmaceutical companies have not obtained a license. Pharmaceutical companies have promoted AAPs for off-label indications to increase sales and consequently have been fined by the US FDA for this. Since the 1990s, AAP use has expanded considerably, for example, the off-label use of quetiapine alone accounted for an estimated 17% of the AAP spend in New Zealand in 2010. There are a number of potential problems with the expanded use of AAPs outside of schizophrenia and related psy-choses. A larger population will be exposed to their adverse effects, which include weight gain, type 2 diabetes mellitus, sudden cardiac death and in-creased mortality rates in the elderly with dementia. There are also concerns with the abuse of these agents, in particular quetiapine. Given that an increasing percentage of the population is being treated with these agents, off-label prescribing of AAPs is a cause for concern; they have a propensity to cause significant side effects and their efficacy and long-term safety for most off-label indications remains largely unknown, and therefore the risks and benefits of their use should be carefully weighed up prior to prescribing these agents off-label.


Related Articles

  • Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Ramaswamy, Krishnan; Kozma, Chris M.; Nasrallah, Henry // Drug Safety;2007, Vol. 30 Issue 7, p589 

    Background: Atypical antipsychotics have been associated with metabolic abnormalities including impaired glucose metabolism, exacerbation of existing diabetes mellitus and new-onset type 2 diabetes. Not all atypical antipsychotic agents appear to have the same propensity to cause...

  • Olanzapine.  // Reactions Weekly;4/15/2006, Issue 1097/1098, p20 

    Presents a case report of a man who experienced exacerbation of type 2 diabetes mellitus during treatment with olanzapine for schizophrenia. Complications presented during the treatment; Treatment with risperidone after discontinuing olanzapine treatment; Level of his glycosylated haemoglobin...

  • Clinical. James, Abigail // Nurse Prescribing;2015, Vol. 13 Issue 12, p580 

    No abstract available.

  • Schizophrenia: Optimal therapy with second-generation antipsychotic agents. Patel, Krina H.; Hlavinka, Peter F. // Pharmacy Today;Nov2007, Vol. 13 Issue 11, Special section p73 

    Objective: To describe symptoms of schizophrenia and present current concepts about optimal use of second-generation, or atypical, antipsychotic agents (SGAs) in its treatment, Data sources: Conducted manually by the authors. Study selection: Not applicable. Data extraction: Not applicable. Data...

  • Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Almoguera, B; Riveiro-Alvarez, R; Lopez-Castroman, J; Dorado, P; Vaquero-Lorenzo, C; Fernandez-Piqueras, J; Llerena, A; Abad-Santos, F; Baca-García, E; Dal-Ré, R; Ayuso, C // Pharmacogenomics Journal;Apr2013, Vol. 13 Issue 2, p197 

    Risperidone non-compliance is often high due to undesirable side effects, whose development is in part genetically determined. Studies with genetic variants involved in the pharmacokinetics and pharmacodynamics of risperidone have yielded inconsistent results. Thus, the aim of this study was to...

  • Selenium: Supplementation and Type 2 Diabetes Mellitus. Hardy, Mary // Travel Medicine Advisor;Nov2007, Vol. 17 Issue 11, p63 

    The article focuses on a study that assesses the effectiveness of long-term selenium supplementation on the incidence of new onset type 2 diabetes mellitus (DM). It states that the risk for type 2 DM was higher across all subgroups for those taking selenium. Thus, the adverse effect of long-term...

  • The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: Two cohorts, 1875-1924 & 1994-2006 compared. Le Noury, Joanna; Khan, Afshan; Harris, Margaret; Wong, Winnie; Williams, Dawn; Roberts, Tony; Tranter, Richard; Healy, David // BMC Psychiatry;2008, Vol. 8, Special section p1 

    Background: Against a background of interest in rates of diabetes in schizophrenia and related psychoses and claims that data from historical periods demonstrate a link that antedates modern antipsychotics, we sought to establish the rate of diabetes in first onset psychosis and subsequent...

  • Capecitabine.  // Reactions Weekly;5/5/2012, Issue 1400, p12 

    A reference entry for a case of an adverse reaction to capecitabine is presented.

  • Temozolomide.  // Reactions Weekly;8/31/2013, Issue 1467, p35 

    The article discusses the case report of an 8-year-old girl who developed acute myelotoxicity while receiving temozolomide for metastatic diffuse intrinsic pontine glioma.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics